Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ: VSAR), an endocrine-focused biopharmaceutical company, today announced that it has retained Cowen to assist in evaluating possible strategic transactions. The process is aimed at identifying opportunities to diversify the Versartis pipeline, including through potential strategic combinations, in order to leverage the company’s expertise and resources and create value for shareholders.

No assurances can be made as to whether a strategic transaction will be recommended by the Board of Directors, and Versartis does not intend to discuss developments with respect to the evaluation process unless a transaction is approved or disclosure becomes appropriate.

Contacts:

Joshua BrummCOO & CFO (650) 963-8582[email protected]

You May Also Be Interested In

• Solerus Announces Plans for New Growth Fund for High-Net-Worth Investors
• Green Thumb Opens Its 24th Florida Location, RISE Dispensary Port St. Lucie, on August 22
• Electronics Delivery (2026): Same-Day Options for Chargers, Earbuds, Monitors, and Last-Minute Tech Needs by Expert Consumers